Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV.

Hoschler K, Maharjan S, Whitaker H, Southern J, Okai B, Baldevarona J, Turner PJ, Andrews NJ, Miller E, Zambon M.

Vaccine. 2020 Feb 15. pii: S0264-410X(20)30221-8. doi: 10.1016/j.vaccine.2020.02.024. [Epub ahead of print]

PMID:
32070679
2.

Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children.

Turner PJ, Abdulla AF, Cole ME, Javan RR, Gould V, O'Driscoll ME, Southern J, Zambon M, Miller E, Andrews NJ, Höschler K, Tregoning JS.

Clin Exp Immunol. 2020 Feb;199(2):109-118. doi: 10.1111/cei.13395. Epub 2019 Nov 15.

3.

Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV.

Cole ME, Saeed Z, Shaw AT, Guo Y, Höschler K, Winston A, Cooke GS, Fidler S, Taylor GP, Pollock KM.

Sci Rep. 2019 Oct 30;9(1):15650. doi: 10.1038/s41598-019-51961-9.

4.

Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016-2017 and 2017-2018 Influenza Seasons in the United Kingdom.

Jackson D, Pitcher M, Hudson C, Andrews N, Southern J, Ellis J, Höschler K, Pebody R, Turner PJ, Miller E, Zambon M.

Clin Infect Dis. 2019 Aug 13. pii: ciz719. doi: 10.1093/cid/ciz719. [Epub ahead of print]

PMID:
31642899
5.

Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial.

L'huillier AG, Ferreira VH, Hirzel C, Natori Y, Slomovic J, Ku T, Hoschler K, Ierullo M, Selzner N, Schiff J, Singer LG, Humar A, Kumar D.

J Infect Dis. 2020 Jan 1;221(1):53-62. doi: 10.1093/infdis/jiz471.

PMID:
31550354
6.

Complexities in predicting the immunogenicity of live attenuated influenza vaccines.

Lindsey BB, Höschler K, de Silva TI.

Clin Infect Dis. 2019 Aug 14. pii: ciz773. doi: 10.1093/cid/ciz773. [Epub ahead of print] No abstract available.

7.

End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18.

Pebody R, Djennad A, Ellis J, Andrews N, Marques DFP, Cottrell S, Reynolds AJ, Gunson R, Galiano M, Hoschler K, Lackenby A, Robertson C, O'Doherty M, Sinnathamby M, Panagiotopoulos N, Yonova I, Webb R, Moore C, Donati M, Sartaj M, Shepherd SJ, McMenamin J, de Lusignan S, Zambon M.

Euro Surveill. 2019 Aug;24(31). doi: 10.2807/1560-7917.ES.2019.24.31.1800488.

8.

Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study.

Lindsey BB, Jagne YJ, Armitage EP, Singanayagam A, Sallah HJ, Drammeh S, Senghore E, Mohammed NI, Jeffries D, Höschler K, Tregoning JS, Meijer A, Clarke E, Dong T, Barclay W, Kampmann B, de Silva TI.

Lancet Respir Med. 2019 Aug;7(8):665-676. doi: 10.1016/S2213-2600(19)30086-4. Epub 2019 Jun 21.

9.

Serological surveillance of influenza in an English sentinel network: pilot study protocol.

de Lusignan S, Borrow R, Tripathy M, Linley E, Zambon M, Hoschler K, Ferreira F, Andrews N, Yonova I, Hriskova M, Rafi I, Pebody R.

BMJ Open. 2019 Mar 8;9(3):e024285. doi: 10.1136/bmjopen-2018-024285.

10.

A Haemophilus sp. dominates the microbiota of sputum from UK adults with non-severe community acquired pneumonia and chronic lung disease.

Wootton DG, Cox MJ, Gloor GB, Litt D, Hoschler K, German E, Court J, Eneje O, Keogan L, Macfarlane L, Wilks S, Diggle PJ, Woodhead M, Moffatt MF, Cookson WOC, Gordon SB.

Sci Rep. 2019 Feb 20;9(1):2388. doi: 10.1038/s41598-018-38090-5.

11.

Humoral response to natural influenza infection in solid organ transplant recipients.

Hirzel C, Ferreira VH, L'Huillier AG, Hoschler K, Cordero E, Limaye AP, Englund JA, Reid G, Humar A, Kumar D; Influenza in Transplant Study Group.

Am J Transplant. 2019 Aug;19(8):2318-2328. doi: 10.1111/ajt.15296. Epub 2019 Mar 18.

PMID:
30748090
12.

A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoietic stem cell transplant.

Miller PDE, de Silva TI, Leonard H, Anthias C, Hoschler K, Goddard K, Peggs K, Madrigal A, Snowden JA.

Vaccine. 2019 Jan 14;37(3):452-457. doi: 10.1016/j.vaccine.2018.11.061. Epub 2018 Dec 13.

13.

Responses to live attenuated influenza vaccine in children vaccinated previously with Pandemrix (ASO3B adjuvanted pandemic A/H1N1pdm09).

Höschler K, Southern J, Thompson C, Warburton F, Andrews NJ, Miller E, Zambon M.

Vaccine. 2018 May 17;36(21):3034-3040. doi: 10.1016/j.vaccine.2018.04.017. Epub 2018 Apr 19.

PMID:
29680198
14.

A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients.

Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P, Rotstein C, Lilly L, Schiff J, Singer L, Humar A, Kumar D.

Clin Infect Dis. 2018 May 17;66(11):1698-1704. doi: 10.1093/cid/cix1082.

PMID:
29253089
15.

Influenza vaccine: going through a sticky patch.

Höschler K, Zambon MC.

Lancet. 2017 Aug 12;390(10095):627-628. doi: 10.1016/S0140-6736(17)31364-8. Epub 2017 Jun 27. No abstract available.

PMID:
28666679
16.

Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity.

de Silva TI, Gould V, Mohammed NI, Cope A, Meijer A, Zutt I, Reimerink J, Kampmann B, Hoschler K, Zambon M, Tregoning JS.

J Immunol Methods. 2017 Oct;449:1-6. doi: 10.1016/j.jim.2017.06.008. Epub 2017 Jun 21.

17.

A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.

Natori Y, Humar A, Lipton J, Kim DD, Ashton P, Hoschler K, Kumar D.

Bone Marrow Transplant. 2017 Jul;52(7):1016-1021. doi: 10.1038/bmt.2017.24. Epub 2017 Mar 6.

PMID:
28263288
18.

Heterologous Immune Responses to Influenza Vaccine in Kidney Transplant Recipients.

Kumar D, Ferreira VH, Campbell P, Hoschler K, Humar A.

Am J Transplant. 2017 Jan;17(1):281-286. doi: 10.1111/ajt.13960. Epub 2016 Aug 9.

19.

Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies.

Héquet D, Pascual M, Lartey S, Pathirana RD, Bredholt G, Hoschler K, Hullin R, Meylan P, Cox RJ, Manuel O.

Vaccine. 2016 Jun 30;34(31):3576-83. doi: 10.1016/j.vaccine.2016.05.021. Epub 2016 May 21.

PMID:
27219339
20.

Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity.

Eichelberger MC, Couzens L, Gao Y, Levine M, Katz J, Wagner R, Thompson CI, Höschler K, Laurie K, Bai T, Engelhardt OG; ELLA study participants, Wood J.

Vaccine. 2016 Jan 20;34(4):458-465. doi: 10.1016/j.vaccine.2015.12.022. Epub 2015 Dec 18.

21.

Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.

Kumar D, Campbell P, Hoschler K, Hidalgo L, Al-Dabbagh M, Wilson L, Humar A.

Transplantation. 2016 Mar;100(3):662-9. doi: 10.1097/TP.0000000000000861.

PMID:
26335915
22.

Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.

Cox RJ, Major D, Pedersen G, Pathirana RD, Hoschler K, Guilfoyle K, Roseby S, Bredholt G, Assmus J, Breakwell L, Campitelli L, Sjursen H.

PLoS One. 2015 Jul 6;10(7):e0131652. doi: 10.1371/journal.pone.0131652. eCollection 2015.

23.

International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE.

Laurie KL, Engelhardt OG, Wood J, Heath A, Katz JM, Peiris M, Hoschler K, Hungnes O, Zhang W, Van Kerkhove MD; CONSISE Laboratory Working Group participants.

Clin Vaccine Immunol. 2015 Aug;22(8):957-64. doi: 10.1128/CVI.00278-15. Epub 2015 Jun 24.

24.

Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations.

Eidem S, Tete SM, Jul-Larsen Å, Hoschler K, Montomoli E, Brokstad KA, Cox RJ.

Vaccine. 2015 Aug 7;33(33):4146-54. doi: 10.1016/j.vaccine.2015.05.081. Epub 2015 Jun 7.

PMID:
26057137
25.

Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.

Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q.

Antiviral Res. 2015 Feb;114:106-12. doi: 10.1016/j.antiviral.2014.12.008. Epub 2014 Dec 13.

PMID:
25513756
26.

Longevity and determinants of protective humoral immunity after pandemic influenza infection.

Sridhar S, Begom S, Hoschler K, Bermingham A, Adamson W, Carman W, Riley S, Lalvani A.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):325-32. doi: 10.1164/rccm.201410-1798OC.

27.

Modern twist on a classic formula for influenza vaccination.

Höschler K, Thompson CI.

Lancet Infect Dis. 2014 Dec;14(12):1165-6. doi: 10.1016/S1473-3099(14)70996-X. Epub 2014 Oct 30. No abstract available.

PMID:
25455969
28.

Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.

Pedersen GK, Sjursen H, Nøstbakken JK, Jul-Larsen Å, Hoschler K, Cox RJ.

Hum Vaccin Immunother. 2014;10(8):2408-16. doi: 10.4161/hv.29583.

29.

Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.

Pedersen GK, Höschler K, Øie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ.

Vaccine. 2014 Jul 31;32(35):4550-7. doi: 10.1016/j.vaccine.2014.06.009. Epub 2014 Jun 18.

PMID:
24950357
30.

International flight-related transmission of pandemic influenza A(H1N1)pdm09: an historical cohort study of the first identified cases in the United Kingdom.

Young N, Pebody R, Smith G, Olowokure B, Shankar G, Hoschler K, Galiano M, Green H, Wallensten A, Hogan A, Oliver I.

Influenza Other Respir Viruses. 2014 Jan;8(1):66-73. doi: 10.1111/irv.12181. Epub 2013 Nov 7.

31.

Incidence of influenza A(H1N1)pdm09 infection, United Kingdom, 2009-2011.

Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Van Kerkhove MD, Lalvani A.

Emerg Infect Dis. 2013 Nov;19(11):1866-9. doi: 10.3201/eid1911.130295.

32.

Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.

Hoschler K, Andrews NJ, Faust SN, Finn A, Pollard AJ, Snape MD, Walker WT, Zambon M, Miller E.

Clin Infect Dis. 2014 Jan;58(2):181-7. doi: 10.1093/cid/cit692. Epub 2013 Oct 22.

PMID:
24149079
33.

Population susceptibility to North American and Eurasian swine influenza viruses in England, at three time points between 2004 and 2011.

Hoschler K, Thompson C, Casas I, Ellis J, Galiano M, Andrews N, Zambon M.

Euro Surveill. 2013 Sep 5;18(36):pii=20578.

34.

Cellular immune correlates of protection against symptomatic pandemic influenza.

Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A.

Nat Med. 2013 Oct;19(10):1305-12. doi: 10.1038/nm.3350. Epub 2013 Sep 22.

PMID:
24056771
35.

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC.

Mol Ther. 2014 Jan;22(1):233-8. doi: 10.1038/mt.2013.162. Epub 2013 Jul 8.

36.

Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.

Muller RB, Maier R, Hoschler K, Zambon M, Ludewig B, Herrmann M, Schulze-Koops H, von Kempis J.

Clin Exp Rheumatol. 2013 Sep-Oct;31(5):723-30. Epub 2013 Jun 14.

PMID:
23806224
37.

Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses.

Mahallawi WH, Kasbekar AV, McCormick MS, Hoschler K, Temperton N, Leong SC, Beer H, Ferrara F, McNamara PS, Zhang Q.

J Virol. 2013 May;87(10):5331-9. doi: 10.1128/JVI.03547-12. Epub 2013 Mar 6.

38.

Comparing the immunogenicity of AS03-adjuvanted 2009 pandemic H1N1 vaccine with clinical protection in priority risk groups in England.

Yung CF, Andrews N, Hoschler K, Miller E.

PLoS One. 2013;8(2):e56844. doi: 10.1371/journal.pone.0056844. Epub 2013 Feb 22.

39.

Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients.

Baluch A, Humar A, Eurich D, Egli A, Liacini A, Hoschler K, Campbell P, Berka N, Urschel S, Wilson L, Kumar D.

Am J Transplant. 2013 Apr;13(4):1026-1033. doi: 10.1111/ajt.12149. Epub 2013 Feb 13.

40.

Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine.

Puleston R, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I, Myles P, Enstone J, Augustine G, Davis Y, Zambon M, Nicholson K, Nguyen-Van-Tam J.

PLoS One. 2013;8(1):e47448. doi: 10.1371/journal.pone.0047448. Epub 2013 Jan 23.

41.

Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011.

Hoschler K, Thompson C, Andrews N, Galiano M, Pebody R, Ellis J, Stanford E, Baguelin M, Miller E, Zambon M.

Emerg Infect Dis. 2012 Nov;18(11):1894-7. doi: 10.3201/eid1811.120720.

42.

Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012.

Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, Hoschler K, Brown K, Galiano M, Myers R, Pebody RG, Green HK, Boddington NL, Gopal R, Price N, Newsholme W, Drosten C, Fouchier RA, Zambon M.

Euro Surveill. 2012 Oct 4;17(40):20290.

43.

Humoral immune response following seasonal influenza vaccine in islet transplant recipients.

Silva M, Humar A, Shapiro AM, Senior P, Hoschler K, Baluch A, Wilson LE, Kumar D.

Cell Transplant. 2013;22(3):469-76. doi: 10.3727/096368912X656135. Epub 2012 Sep 21.

PMID:
23006439
44.

Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients.

Orcurto A, Pascual M, Hoschler K, Aubert V, Meylan P, Manuel O.

Transplantation. 2012 Sep 27;94(6):630-6.

PMID:
22895612
45.

T-helper 1 cells elicited by H5N1 vaccination predict seroprotection.

Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ.

J Infect Dis. 2012 Jul 15;206(2):158-66. doi: 10.1093/infdis/jis330. Epub 2012 May 2.

PMID:
22551811
46.

Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting.

Laurie KL, Huston P, Riley S, Katz JM, Willison DJ, Tam JS, Mounts AW, Hoschler K, Miller E, Vandemaele K, Broberg E, Van Kerkhove MD, Nicoll A.

Influenza Other Respir Viruses. 2013 Mar;7(2):211-24. doi: 10.1111/j.1750-2659.2012.0370a.x. Epub 2012 Apr 30.

47.

Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy.

Parry RP, Tettmar KI, Hoschler K, Brailsford SR, Samuel D, Ashford M, Maclennan S, Williamson LM, Tedder RS.

Vox Sang. 2012 Aug;103(2):107-12. doi: 10.1111/j.1423-0410.2012.01599.x. Epub 2012 Mar 9.

PMID:
22404076
48.

H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.

Walker WT, de Whalley P, Andrews N, Oeser C, Casey M, Michaelis L, Hoschler K, Harrill C, Moulsdale P, Thompson B, Jones C, Chalk J, Kerridge S, John TM, Okike I, Ladhani S, Tomlinson R, Heath PT, Miller E, Faust SN, Snape MD, Finn A, Pollard AJ.

Clin Infect Dis. 2012 Mar 1;54(5):661-9. doi: 10.1093/cid/cir905. Epub 2012 Jan 19.

49.

A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.

de Whalley P, Walker W, Snape MD, Oeser C, Casey M, Moulsdale P, Harrill C, Andrews N, Hoschler K, Thompson B, Jones C, Chalk J, Kerridge S, Tomlinson R, Heath PT, Finn A, Faust S, Miller E, Pollard AJ.

Health Technol Assess. 2011 Dec;15(45):v-vi, xi-xiii, 1-128. doi: 10.3310/hta15450.

50.

Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard.

Wood JM, Major D, Heath A, Newman RW, Höschler K, Stephenson I, Clark T, Katz JM, Zambon MC.

Vaccine. 2012 Jan 5;30(2):210-7. doi: 10.1016/j.vaccine.2011.11.019. Epub 2011 Nov 17.

PMID:
22100887

Supplemental Content

Loading ...
Support Center